A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.
The panel brought oncologists, cardiologists and hypertension experts together to draft new recommendations for physicians prescribing angiogenesis inhibitors for the treatment of cancer. First approved in the mid-2000's, these drugs disrupt tumor growth by preventing the formation of new blood vessels, but also increase blood pressure in most patients.